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Box start
Box 1. What you need to know
 We do not know how well HPV vaccination will protect against cervical cancer. 
Trials have not focused on the outcome of cervical cancer because they had too few 
participants and didn’t follow them up for long enough:  cervical cancer may take 
decades to develop.  
 Published numbers from RCTs (randomized controlled trials) may overstate 
efficacy because: a) testing occurred too frequently in the trials when, in real world 
settings, lesions may regress spontaneously; b) trials used composite surrogate 
outcomes, some of which, such as HPV-infection and CIN1, occur more frequently 
than others and are very unlikely to progress to cancer; and c) subgroups were over-
analyzed.  
 The trial populations have limited relevance and validity for real world settings: for 
example, women in the trials were older than the target population; we don’t have 
enough data on the benefits in women who may have been exposed to HPV before 
they were vaccinated and who do not know their HPV status. 
 We do not have enough data on the impact of the vaccine on CIN3, which is more 
likely than CIN 1 and 2 to progress to cervical cancer. We also have less data on the 
impact on cervical disease due to any HPV type rather than just lesions due to HPV 
16 and 18. 
 Women should still attend regular cervical screening because efficacy in preventing 
cervical pre-cursors is <100% and there are more oncogenic types than those 
covered by the vaccines. We have good evidence that cervical screening 
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significantly reduces the risk of cervical cancer in women regardless of whether 
they have been vaccinated. The number of new cancers and deaths have fallen 
markedly such that cervical cancer now accounts for only 1% of cancer deaths in 
women in the UK (854 deaths in 2016).(1) 
 Information from the trials can tell us what happens between 5-9 years after 
vaccination, but we do not know if protection wanes after this time.
 A recent observational study provides some evidence of efficacy against CIN3+ in 
girls vaccinated before sexual debut. Ongoing observational studies may tell us 
about the long term effect on rates of cervical cancer, but it will take many years 
before we have the evidence. 
Box end
The HPV vaccination programme aims to prevent cervical cancer. Globally around 
13.1/100,000 women are diagnosed with cervical cancer each year.(2) Typically 
vaccination is offered to girls aged nine to 13 before sexual debut and naïve to HPV 
infection. Box 2 gives an overview of licensing and indications in Europe and the US.
Box start
Box 2. Licensing and guidelines
Licensing
• Gardasil, Gardasil 9, and Cervarix vaccines have been approved for marketing and 
use in females and males from the age of 9 throughout the world to prevent cervical 
cancer.
• The European Medicines Agency (EMA) and US Food and Drug Administration 
(FDA) granted marketing approval for Gardasil in 2006, and for Cervarix in 2007 
and 2009 respectively.
• Gardasil 9 was approved in 2014 by the FDA and in 2015 by the EMA, but it is not 
currently used in the UK.
• The EMA has licensed all three vaccines for females and males with no upper age 
limit. The FDA has licensed Gardasil up to age 26 and Gardasil 9 up to age 45 for 
females and males, and Cervarix for females only up to age 25. 
Guidelines
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 The US Centers for Disease Control and Prevention recommends “routine 
vaccination at age 11 or 12 years. (Vaccination can be started at age 9.) ACIP 
[Advisory Committee on Immunization Practices] also recommends vaccination for 
females aged 13 through 26 years not adequately vaccinated previously”.(3)
 The UK uses Gardasil. Public Health England advises girls to be vaccinated from 
age 12 to 18 years. Immunisation Scotland offer the vaccine for girls aged 11 to 13 
years. There is a planned roll-out to boys aged 12-13 in England and Scotland.
Box end
Public health agencies promote the position that the vaccine has been shown to 
prevent cervical cancer (see Supplement 1). Not all routinely emphasize the limitations 
of the evidence or the uncertainties which we will discuss. 
Background 
A key issue for the design of trials and studies of efficacy is the complexity of 
the epidemiology of the HPV subtypes and the lesions used as surrogate endpoints for 
cervical cancer each with their own different natural histories, prevalence and incidence 
and strength of association with cancer.  These measures especially if combined as 
composite surrogate endpoints in trials generate new uncertainties. 
i) HPV infection
There are 100+ types of the human papillomavirus (HPV): twelve of which are 
carcinogenic to humans, according to the IARC (International Association of Cancer 
Research).(4) Types vary in prevalence, as does their association with cervical cancer. 
HPV vaccines are licensed for use against oncogenic HPV types 16 and 18 and now 31, 
33, 45, 52, 58 in Gardasil-9. Gardasil and Gardasil-9 are also licensed against non-
oncogenic types 6 and 11 linked to genital warts. 
The lifetime risk of an incident HPV infection is 79%,(5) the majority of HPV 
infections are transient and 67% clear within one year.(6) Around 10% of women 
without CIN have HPV infection at any one time.(7) The mechanism of progression 
from HPV infection to cervical cancer and its precursors is not well understood.(4, 8-
11) 
ii) Cervical cancer and pre-cancerous lesions as surrogate endpoints
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Estimated rates of regression and progression for CIN 1, 2 and 3 are presented 
in Figure 2.(12) However there remain uncertainties due to methodological issues in the 
epidemiological studies from which these findings originate.(12)
The IARC has acknowledged that composite endpoints in intervention studies 
involving CIN2 are sub-optimal(13) as CIN2 is often misclassified due to its diagnosis 
having lower reproducibility and validity.(14) Women with CIN2 are currently offered 
treatment which complicates research into progression to CIN3.
CIN3 can develop via progression of CIN1 and CIN2 or directly as a result of 
HPV infection, so CIN1 and CIN2 may not be good predictors of progression. Rate of 
progression from CIN3 to invasive cancer is likely to be higher than Ostor’s estimate of 
>12%.(12) Lifetime risk may be up to 40% without cervical screening and 
treatment.(15)
Aim 
To describe the uncertainties generated by the design of phase 2 and 3 efficacy 
trials and use this to interpret available efficacy data on prevention of cervical cancer 
and its precursors.
Methods and analysis 
We searched Embase and Medline for papers relating blinded controlled trials 
of HPV vaccination in females considering efficacy against cervical cancer and its 
precursors. See Supplement 3 for search strategy. No trial has tested Gardasil and 
Cervarix vaccines head to head using clinical outcomes (rather than immunological 
outcomes). We reviewed 35 published papers relating to 12 published randomised 
blinded non-HPV vaccine-controlled phase 2 and 3 trials of Gardasil and Cervarix 
conducted from 2001 to 2016 assessing efficacy against cervical cancer and its 
precursors (Table 1). Throughout this article, we refer to trials by their protocol name 
as presented in bold in Table 2. But for trials 104798 and 107638, we use the name of 
their first authors, Konno and Zhu respectively.
We excluded trials of the HPV-16 monovalent vaccine (as it was not licensed 
and data suggest it had different pharmacodynamics to Gardasil and Cervarix (16)) and 
the one efficacy trial of Gardasil-9 (as the control was Gardasil, not a placebo).(17) All 
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the efficacy studies used an active vaccine (Hepatitis A) as the control, or a control 
containing an aluminium-adjuvant, rather than a true placebo, this in itself has raised 
concerns.(11) We chose to focus on RCTs as this offers the highest level of evidence 
and this is the evidence used for decisions by regulatory bodies and decisions on 
initiating vaccination programmes.
We also found 39 meta-analyses and systematic reviews of HPV vaccine 
efficacy; of them many are restricted to post-hoc analyses of subgroups and have 
inappropriately combined trials in the same analysis e.g. for different vaccines (see 
Supplement 4). The 2018 Cochrane review(18) has been criticised for failing to include 
all relevant trials; ignoring evidence of harms; and using composite endpoints with 
different natural histories.(19)
We compared the eligibility criteria, testing methods for HPV and cervical 
lesions, outcomes measures, length of follow up, target group and sub-group definitions 
of the different trials. We focuse  on the evidence for efficacy for CIN3+ and 12-month 
persistent infection which are deemed the more stringent outcome measures.
<<Insert Figure 1. Phase 2 and 3 RCTs on HPV vaccination efficacy>>
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Table 1. All phase 2 and 3 trials by vaccine and control, sponsor, country, start and end dates, number and age of participants and 
length of follow-up.
Vaccine & Control Trial name, 
NCT number  
(and sponsor)
Research papers Phase Country Start date End date Number of 
participants
Age At 
Enrolment
Average (mean) length of 
follow-up
Cervarix vs. 
Aluminium-
hydroxide containing 
control
HPV-001/ 
580299
NCT00689741
(GSK)
Harper 04(20) 2 USA (incl. Puerto Rico), 
Brazil, Canada 
Jan-01 Apr-03 1113 15-25 Up to 27 months (average not 
given)
Cervarix vs. Placebo
Aluminium-
hydroxide containing 
control
HPV-007; 
follow-on study 
from HPV-001
NCT00120848
(GSK)
Harper 06,(21) 
Romanowski 09(22)
2 USA, Brazil, Canada Nov-03 Aug-07 776 15-25 5.9 years from 1st vaccination
Cervarix vs. 
Aluminium-
hydroxide containing 
control
HPV-023/ 
109616; follow-
on study from 
HPV-001 and 
HPV-007
NCT00518336
(GSK)
De Carvalho 10,(23) 
Roteli-Martins 12,(24) 
Naud 14(25)
2 Brazil Nov-07 Jul-08 437 15-25 8.9 years from 1st vaccination
Cervarix vs. Hepatitis 
A vaccine
104798 (Konno)
NCT00316693
(GSK)
Konno Apr 10,(26) Konno 
Jul 10(27)
2 Japan Apr-06 Feb-09 1040 20-25 24 month after 1st vaccination
Cervarix vs. Hepatitis 
A vaccine
PATRICIA/ 
HPV-008
NCT00122681
(GSK)
Paavonen 07,(28) 
Paavonen 09,(29) Lehtinen 
12,(30) Wheeler 12,(31) 
Palmroth 12,(32) 
Szarewski 12,(33)
Apter 15,(34) Struyf 15(35) 
3 USA, Australia, Belgium, 
Brazil, Canada, Finland, 
Germany, Italy, Mexico, 
Philippines, Spain, Taiwan, 
Thailand, UK
May-04 Nov-09 18644 15-25 Mean 43.7 months (median 47.4) 
Cervarix vs. Hepatitis 
A vaccine
Costa Rica 
Vaccine Trial/ 
CVT/ HPV-009
NCT00128661
Herrero 11,(36) Kreimer 
11,(37) Rodriguez 13,(38) 
Hildesheim 14,(39) 
Hildesheim 16,(40) 
3 Costa Rica Jun-04 
(initiation 
into trial)
Dec-10 
(final data 
collection 
for 
7465 18-25 53.8 mths
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(NCI & GSK) Beachler 16(41) primary 
outcome)
Cervarix vs. 
Aluminium-
hydroxide containing 
control
VIVIANE/ 
HPV-015/ 
104820
NCT00294047
(GSK)
Skinner 14,(42) Wheeler 
16(43)
3 Australia, Canada, Mexico, 
Netherlands, Peru, 
Philippines, Portugal, Russia, 
Singapore, Thailand, UK, 
USA
Feb-06 Jan-14 5747 26+ 5.9 years TVC from 1st 
vaccination, 5.7 years in ATP-E 
group from 3rd vaccination
Cervarix vs. 
Aluminium-
hydroxide containing 
control
107638/ Zhu
NCT00779766
(GSK)
Zhu 14,(44) Zhu 17(45) 3 China Oct-08 Oct-14 6051 18-25 Mean 57 months TVC-E  from 
1st vaccination, 52 months ATP-
E group from 3rd vaccination 
Gardasil vs.   
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
V501-007
NCT00365716
(Merck)
Villa 05,(46) Villa 06(47) 2 Brazil, Finland, Sweden, 
Norway, USA
May-00 May-04 552 (initial 
study up to 3 
years), 241 
(extension 
study up to 5 
years)
16-23 Initial study up to 36 months 
(average not given). Extension 
study up to 5 years (results given 
for 226 women who completed 
study to 60 months, average not 
given)
Gardasil vs. 
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
FUTURE I/ 
V501-013
NCT00092521
(Merck)
Garland 07(48) 3 Australia, Austria, Brazil, 
Canada, Colombia, Czech 
Republic, Germany, Hong 
Kong, Italy, Mexico, New 
Zealand, Russia, Thailand, 
UK, and USA (incl. Puerto 
Rico) 
Dec-01 Jul-07 5455 16-24 Average 3 years from 1st 
vaccination
Gardasil vs. 
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
FUTURE II/ 
V501-015
NCT00092534
(Merck)
Future II Study Group(49) 3 Brazil, Colombia, Denmark, 
Finland, Iceland, Mexico, 
Norway, Peru, Poland, 
Singapore, Sweden, UK, and 
USA (incl. Puerto Rico)
Jun-02 Jul-07 12167 15-26 Average 3 years from 1st 
vaccination
Gardasil vs. 
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
FUTURE III/ 
V501-019 
NCT00090220
(Merck)
Munoz 09,(50) 
Castellsague 11(51)
3 Colombia, France, Germany, 
Philippines, Thailand, USA, 
Spain
Jun-04 May-09 3819 24-45 Median 4 years (mean 3.8 years)
Gardasil vs. 
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
V501-027
NCT00378560
(Merck)
Yoshikawa 13(52) 2 Japan Jun-06 Sep-09 1021 18-26 30 months (23 months after 
month 7)
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Gardsasil vs.  
Aluminium
hydroxyphosphate 
sulfate adjuvant 
containing control
V501-041
NCT00834106
(Merck)
Wei 18(53) 3 China Jan-09 Sep-16 3006 20-45 Mean 6.07 years after first 
vaccination
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<<Insert Fig 2 here>>
Does HPV vaccine prevent cervical cancer?
None of the trials were designed to determine efficacy or effectiveness against 
cervical cancer. There were no reported cases of cervical cancer in any trials; one case 
of vulval carcinoma was reported in the vaccinated group of FUTURE I.(48)
The time between first exposure to HPV and peak development of CIN3 is 7-10 
years.(13) It takes a further 10 years or so for cervical cancer to develop, according to 
natural history studies.(13) All trials had a mean length of follow-up of six or fewer 
years, apart from the HPV-023 extension with mean follow-up 8.9 years.
Does HPV vaccine prevent pre-cancerous lesions?
There were eight powered outcomes relating to cervical disease used across the 
trials, all of which were surrogates or composite surrogate outcomes (see Table 2). 
Surrogate outcomes are biomarkers used as substitutes for clinical endpoints and used 
to predict an intervention’s benefits. Key pre-marketing trials evaluated the effect of 
HPV vaccines against precancerous lesions, endpoints that were accepted by authorities 
as a surrogate for cervical cancer. There are limitations to surrogate outcomes in 
general,(54) and for HPV and cervical cancer. Using composite surrogate outcomes 
(combining two or more surrogate outcomes together) is problematic because of 
differences in epidemiology and their natural history and management - see 
Background and Figure 2. Five of the 12 trials (VIVIANE, V01-007, FUTURE III, 
V501-027, V501-041) were powered for composite outcomes that combined cervical 
disease and persistent HPV infection.(43, 47, 51-53) Four trials combined cervical 
disease and genital warts in the same primary outcome (FUTURE III, V501-007 and 
V501-027, V501-041) thereby inflating efficacy measures.(47, 51-53)
Table 2. Powered endpoints across trials
Powered endpoint Number 
of trials 
using the 
endpoint 
Vaccine: Trials using the 
endpoint
HPV 16/18 incident infection 1 
Cervarix: HPV-001/007/023
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HPV 16/18 12-month persistent infection 1 Cervarix: CVT
HPV 16/18 6-month persistent infection 1 Cervarix: Konno
HPV 6/11/16/18 CIN1+ 1 Gardasil: FUTURE I
HPV 16/18 CIN2+ 5 Cervarix: CVT, PATRICIA, Zhu
Gardasil: FUTURE II, V501-041
HPV 16/18 6-month persistent infection 
or CIN1+
2 Cervarix: VIVIANE, Zhu
HPV 16/18 6-month persistent infection 
or external genital lesions or CIN1+
1 Gardasil: FUTURE III
HPV 6/11/16/18 6-month persistent 
infection or external genital lesions or 
CIN1+
4 Gardasil: V501-007, FUTURE III, 
V501-027, V501-041
CIN1+
The trial outcomes included surrogates CIN1 and CIN2, which are more common than 
CIN3/AIS and cervical cancer, but which often regress and are of limited clinical 
concern (see Background and Figure 2). For example, intervention is not recommended 
for CIN1. Seven trials (FUTURE I, VIVIANE, V01-007, FUTURE III, V501-027, Zhu, 
V501-041) included CIN1 with CIN2, CIN3 and AIS in the same primary outcome 
(making a composite outcome), potentially inflating vaccine efficacy as there are many 
more CIN1 cases than CIN2+.(43, 45, 47, 48, 51-53)
 
CIN2+
The incidence (rate of detection) of CIN2, CIN3 and AIS in the trials was low so 
although many trials showed high efficacy for the vaccine, this was in the context of 
very few cases of CIN 2+. For example, the HPV-023 trial showed high vaccine 
efficacy (100% against CIN2 and CIN3 over nine years follow-up) with very low 
incidence (only three cases, all in the control group, out of 212 participants).(25) The 
trials were powered for the minimum number of events needed to obtain a statistically 
significant result, and many trials were designed to stop once this number had been 
achieved. But the powered outcomes often included CIN1, which means those trials 
were not powered to reach a minimum number of higher-grade CIN cases. Instead of 
multiple short duration trials, this problem of power could have been overcome by 
having one large trial of longer duration in each country. 
CIN3+
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CIN3 is generally agreed to be the best marker for risk of cervical cancer, with rates 
of progression of at least 12%.(12) New evidence suggests that clinical intervention 
following detection on screening may be best reserved for women with CIN3.(55) Only 
three of the 12 trials (FUTURE I, FUTURE II, PATRICIA) reported CIN3+ or AIS in 
subgroups that represented the target population of women naïve to HPV (see Table 
4).(30, 49, 56) The incidence of AIS in the trials is very low and only three trials 
(FUTURE I, FUTURE II, PATRICIA) published results for AIS alone.(30, 49, 56) 
In these three trials, vaccine efficacy against CIN3 and AIS due to HPV 16/18 was 
100% (see Supplement 5) but there were small numbers and wide confidence intervals, 
sometimes showing non-significance (where the confidence interval crosses zero).(49, 
56) Vaccine efficacy against CIN3 and AIS due to any HPV type varied substantially 
between the vaccines.(30, 56)
What is the evidence that vaccination prevents clinically meaningful HPV 
infection?
It is possible to diagnose new HPV infections (incident) and ongoing infection 
(persistent). Studies have shown median length of HPV 16 infection to be 8.5 to 19.4 
months and HPV 18, 7.8 to 12 months.(13)
The HPV001/007/023 trial used incident infection of HPV 16/18 as the primary 
outcome.(20, 22, 25) The results are not relevant to policy decision making as the 
current consensus reported by the WHO is that incident HPV infection is not an 
adequate surrogate outcome because it rarely progresses to cervical disease.(57) 
There is a lack of agreement on what time period defines persistent infection,(13) 
and the trials may have overestimated vaccine efficacy by picking time periods that are 
shorter than the duration of most self-limiting infections – for example six months. In 
some trials the testing interval for diagnosing six-month persistent infection was four 
months,(36, 47, 52) or five months.(44, 51, 53)
Only one Gardasil trial, V501-041, used 12-month persistent infection as an 
outcome, however the study authors only presented data for combined HPV 6/11/16/18, 
not for 16/18 or any oncogenic type.(53) In the Cervarix trials, 12-month HPV 16/18 
persistent infection vaccine efficacy varied from 85.3% to 100% (see Supplement 
6).(25, 27, 29, 33, 45) Vaccine efficacy for 12-month persistent infection by any 
oncogenic HPV-type ranged from 10.4% to 50.1% across trials with wide confidence 
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intervals for most trials.(25, 27, 29, 33, 45) The results were not statistically significant 
for the HPV-023 trial and Zhu (see Supplement 6).(25, 45)
Not all trials analysed HPV types 16 and 18 separately. The incidence of HPV 
infection varies by HPV type.(30) HPV 18 was much less common than HPV 16. 
Combining their results makes the efficacy against HPV 18 appear more solid. In some 
trials the results for HPV 18 on its own were not statistically significant, and were only 
significant when combined with results for HPV 16. For example, in the per-protocol 
population subgroup of V501-027 the six-month persistent infection or genital disease 
(the trial primary outcome) vaccine efficacy was 100% (59.7,100) for HPV 16, 86.0% 
(-8.9, 99.7) for HPV 18, and 94.5% (65.2, 99.9) for HPV 16/18.(52) In ATP-E 
subgroup of the PATRICIA trial, CIN3+ vaccine efficacy for HPV 16 was 90.2% (59.7, 
98.9), HPV 18: 100% (-8.2, 100) and HPV 16/18: 91.7% (66.6, 99.1) respectively.(30) 
This means the vaccine may ot protect as well against cervical cancer related to HPV-
18. The proportion of cervical cancers related to HPV 18 ranges from 13% in 
South/Central America to 22% in North America.(58)
How much information is there on long term outcomes and how long does 
protection last?
All trials were six or fewer years in length, apart from the extension study HPV-023 
with mean follow-up of 8.9 years, which maintained blinding and kept a control group, 
but only included 437 of the original 1113 participants in HPV-001.(25) The longest 
study of Gardasil was V501-041, which was extended from 30 months to 78 months 
with 2601 out of the initial 3006 participants.(53)
Features of the trials may bias the findings in overestimating long term efficacy. For 
example, HPV 16/18 related CIN3 presents earlier than non-vaccine type CIN3 so 
shorter efficacy trials will be biased in favour of finding HPV 16/18 related CIN3.(59)
Although incidence and progression of disease differ over time and by age, V501-
007 combined the results of participants from the original trial with those who 
completed an extra two-year extension.(47) In HPV-007 and HPV-023, results for 
participants from the preceding trials were considered together.(22, 25)
How similar were the females in the trials to the target vaccination groups?
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Females in the trials are typically older than those in real life vaccine programs, and 
it is unclear whether their outcomes are similar. We don’t know efficacy rates in girls 
aged between 9-13 years. 
The youngest trial participants were aged 15 and trials did not restrict recruitment to 
girls before sexual debut. Therefore previous exposure to HPV is likely for some girls. 
Per-protocol subgroups with much fewer participants were used to analyse those with 
no evidence of previous HPV exposure but as shown earlier, most trials did not present 
data for CIN3+ outcomes in these subgroups.
Efficacy in girls aged 9-13 has been estimated using immunobridging trials (where 
immune response levels are measured) rather than using clinical outcomes.(60) We do 
not know what level of antibody titres define a surrogate level of protection against 
cervical cancer or its precursors and how long protection will last (Gardasil anti-HPV 
18 titres  are not different from natural infection as early as 24 months after 
vaccination).(60) Therefore it is possible that protection will wane by time of peak 
exposure when vaccinated at an earlier age.
Three trials recruited older women (FUTURE III (aged 24-45), VIVIANE (aged 
26+) and V501-041 (aged 20-45)).(42, 50, 53) In VIVIANE a subset of up to 15% of 
women with a history of HPV-associated infection or disease were included (defined as 
two or more abnormal smears in sequence, abnormal colposcopy, or biopsy or 
treatment of the cervix after abnormal smear or colposcopy findings) but this means 
that the Total Vaccine Cohort may not reflect the proportion of women with a history of 
HPV-associated disease in the wider population.(42) There were then restrictions based 
on HPV DNA and serostatus for inclusion in the according to protocol for efficacy and 
total vaccine cohort for efficacy subgroups. In FUTURE III, women with a history of 
past or present genital warts or cervical disease were excluded; and the primary tests of 
efficacy were in the HPV type-specific per-protocol efficacy analyses (PPE), which 
required women to be seronegative to relevant type on day 1 and PCR negative to that 
type in cervicovaginal swabs or biopsy samples, or both, from day 1 until month 7.(50) 
V501-041 excluded women with more than four previous sexual partners and those 
with a history of genital warts or ‘significant cervical disease’- the study authors did not 
specify what this meant.(53)
Seven trials excluded women with more than four to six previous sexual 
partners.(20, 28, 46, 48, 52, 53, 61) Five excluded women with previous abnormal 
cervical smears(20, 46, 48, 52, 61) and an additional three excluded women with a 
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history of previous colposcopy.(26, 28, 44) CVT was the only trial with no restrictions 
based on genital warts or cervical or sexual history.(36) These restrictions may make 
the vaccine appear more efficacious in the ITT population than in the general 
population of women of the same age. In CVT the efficacy in the ITT group for 12-
month persistent infection with any oncogenic HPV type was 11% (95% CI 2.2, 19.5), 
they did not give efficacy against CIN3+ in the ITT group.(36)
There is also global variation in the epidemiology of HPV which means that the 
trial findings may be poorly generalizable to some settings, including Africa - so it is 
important to know if results differ by study region. None of the trials considering 
efficacy outcomes were conducted in Africa (we are only aware of a safety and 
immunogenicity trial in Africa(62)) despite this being the world region with by far the 
highest incidence of cervical cancer.(2) The Cochrane review acknowledges that 
“differences in the populatio  HPV prevalence in the trial sites, or differences in study 
protocols and assays used, may explain the contrast in efficacy” between Cervarix and 
Gardasil.(18)
What is the risk of oncogenic HPV-type substitution?
Vaccines may protect against HPV types, which are not included in the vaccine. 
There was some evidence of cross-protection against three high-risk HPV types (31, 33 
and 45) for Cervarix (see Supplement 7).(31, 36, 43, 45) There was cross-protection 
against one non-vaccine HPV type by Gardasil (31) (see Supplement 7).(63) But there 
was evidence of a statistically significant increased risk of HPV type 51 and 58 in the 
Cervarix trials, compared with the control vaccine.(31, 36) It is unknown whether 
vaccine targeting will lead to substitution by other oncogenic types, as with 
pneumococcal vaccination.(64)
Methodological factors from the trials which may affect interpretation of the 
results
Multiple underpowered analyses
All trials undertook multiple subgroup analyses, which increases the likelihood of 
positive statistical findings in the absence of true effect. The subgroup definitions 
varied across trials, so that results cannot be compared across trials. Results were not 
given for all subgroups, and were not broken down by country, by study site or for each 
outcome. This is important given different epidemiology of HPV in different areas of 
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the world. It may have been reported this way because incidence was low. We have 
included a table giving the different subgroup definitions in Supplement 8.
Problems with reporting of trial results
The trials report vaccine efficacy as the primary outcome, which shows relative risk 
reduction. This can over-emphasise efficacy compared with absolute risk reduction 
such as Numbers Needed to Vaccinate, which is more useful for clinicians, patients and 
policy makers. None of the trials gave Numbers Needed to Vaccinate.- CVT is the only 
trial that presented results in terms of absolute risk reduction.(36, 38, 39) The absolute 
risk reduction for the PATRICIA trial for CIN3+ due to any oncogenic HPV-type (see 
Table 3) (our calculation) is 0.75% , giving a number needed to vaccinate of 133.
Frequency of cervical screening 
All the trials did Pap cytology at 6-12 monthly intervals. Cervical cancer screening 
is recommended in England every three years, between the age of 25 and 49.(65) 
Increased frequency of screening can lead to over-diagnosis and overtreatment of 
cytological abnormalities that would normally resolve and not be detected.(66) 
Increasing the frequency of testing suits early trial completion but may overestimate 
vaccine efficacy.
Testing methods for HPV
The tests for DNA positivity to a particular HPV type (indicating ongoing infection) 
and seropositivity (indicating previous infection) have limited specificity and 
sensitivity.(67) This is another reason HPV infection has limitations as a surrogate of 
cervical cancer. Only 50-70% of HPV infections result in detectable anti-HPV 
responses,(51) and initial seropositive status may revert to negative.(68) So subgroups 
of women considered naïve to HPV may have had previous exposure. Also, latent 
infection may be undetectable on current tests. The IARC has noted that ‘it is not 
known how frequently this [latent infection] occurs in immunocompetent individuals, 
how long it lasts, what causes re-emergence into a detectable state or what fraction of 
cancers arises after a period of latency’.(13) This also raises the question of whether 
subgroups naïve to HPV can reliably represent girls before sexual debut, and whether 
HPV infection is a valid surrogate outcome.
Meta-analysis of limited value due to trial heterogeneity
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Differences in trial endpoints and subgroups limit the ability to compare and 
aggregate data from trials. This is compounded by lack of standardisation across studies 
for a range of measures: tests of previous HPV exposure, serological assays to detect 
HPV infection, and sampling methods including frequency of testing.(67) 
There are no agreed criteria for defining the causal HPV type for clinical lesions, 
and different trials used different criteria (see Supplement 9). There was no standard 
approach to assess efficacy against disease and infection due to HPV types not found in 
the vaccine for example whether they considered non-vaccine oncogenic types or all 
non-vaccine HPV types (see Supplement 10). Given that Merck and GSK were 
involved in all the trials it is unclear why there was no consistency in methods and tests 
across trials. 
Is ongoing research likely to resolve the uncertainties?
The focus of this paper is RCTs, but we have also looked at whether observational 
studies can answer some of the uncertainties, acknowledging that this is a lower level of 
evidence but practically the most likely source of future information in the absence of 
long-term RCTs. We identified 19 Phase 4, observational and non-blinded follow-up 
studies (including a meta-analysis of ecological studies) that are potentially relevant to 
the uncertainties discussed in this paper (see Suppplement 2). None of these studies is 
ideal. Many are small, of short duration, or not looking at CIN3+. One observational 
study (#5) showed a reduction in relative risk of CIN3 amongst those vaccinated of 
0.45.(69) The PATRICIA trial follow-up (#3), the only trial planned for 20 years post-
vaccination, and the Mexican FASTER trial (#18) are likely to provide more long-term 
efficacy data on the more clinically relevant efficacy endpoints.
The recently published observational study conducted in Scotland by Palmer et al  
provides new evidence on reduction of CIN3+ regardless of HPV type.(70) The authors 
note the following limitations which may have inflated measures of efficacy: the study 
gathered data only on the first round of cervical screening at age 20 years (now changed 
to age 25 years in line with England) with underrepresentation of the unvaccinated 
group (23% screening attendance versus 51% in the vaccinated group at aged 20 or 21); 
and shorter follow-up time for women born in 1995 and 1996 necessarily affects the 
robustness of the estimate of vaccine effectiveness for younger women. In addition, the 
basis for the claim of herd protection is not well explained for the unvaccinated women 
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in the 1995-96 cohort, compared with unvaccinated women in 1988-90. Nor do the 
authors consider how changes in sexual activity may have contributed to the observed 
decrease in CIN prevalence independent of the vaccine: between 2002-2014 (the latest 
period for which there are data) the proportion of 15-year olds in Scotland who have 
ever had sex reduced, although socio-economic inequalities persist for sexual initiation 
and condom use.(71) Screening uptake also varies by socioeconomic status.(72)
What should we do in the light of the uncertainty?
Policy
We ask policy makers to:
1. Establish national baseline epidemiological data on cancer incidence, mortality, 
and HPV subtype prevalence to support evidence based decisions about whether the 
currently available vaccines are likely to be cost effective and should be a priority.
2. Ensure that cancer surveillance and registries are in place before any vaccination 
programme is implemented so that changes in incidence of cervical cancer and its 
precursors can be studied. 
3. Initiate national long term efficacy and effectiveness studies that are free of 
industry funding, focus on clinically meaningful outcomes, and enrol and analyse the 
vaccine target populations.
Research
In the UK, cervical screening is estimated to prevent more than 80% of cervical 
cancers.(15) A cost-effectiveness analysis in Australia suggested that immunisation is 
not cost-effective in settings with established cervical screening.(73) We still do not 
know how many cases of cervical disease prevented by vaccination would have been 
detected by cervical screening. Further research is needed on whether adding 
vaccination where screening exists will be cost effective. Box 3 shows our 
recommendations for further research to address uncertainties. We also call for more 
research on HPV to be free from industry funding.
Box start
Box 3: Recommendation for future trials to address the uncertainties:
• Vaccinate prior to onset of sexual activity and begin assessment of endpoints at age of 
usual cervical screening once sexually active
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• Make all clinical study reports including anonymised individual patient data publicly 
available
• Separate trials to assess the benefit in women already exposed to HPV, without 
restrictions based on risk factors
• Analyse data by country and study site
• Ensure the testing interval is in line with usual cervical screening protocols
• Continue follow-up for minimum 20 years from the time of sexual debut
• Power trials for primary composite outcome CIN3/AIS/cervical cancer due to 
oncogenic HPV types
• Define secondary outcome of persistent infection with HPV 16/18 at a minimum of 12 
months
• Use standardised testing methods for HPV detection.
• Undertake a saline placebo-controlled efficacy trial of Gardasil 9 in previously 
unvaccinated participants, as it is difficult to draw conclusions on efficacy and risk 
of harms based on the trial comparing Gardasil 9 against Gardasil.
Box end
Conclusion
This review has revealed many methodological problems with the Phase 2 and 3 
efficacy trials of HPV vaccination leading to uncertainty regarding understanding its 
efficacy. 
1. Cervical cancer - It is uncertain whether HPV vaccination prevents cervical cancer. 
The trials were not designed to detect this outcome, which takes decades to develop. 
For most outcomes, follow up data exist for an average of only four or five years.
2. CIN - There is evidence that vaccination prevents CIN 1; however this is not a 
clinically important outcome (no treatment is given). Trials used composite 
surrogate outcomes which included CIN1, but high efficacy against CIN1+ (CIN1, 
2, 3 and AIS) does not necessarily mean high efficacy against CIN3+ (CIN3 and 
AIS), which occurred much less frequently. There are too few data to clearly 
conclude that HPV vaccine prevents CIN3+. CIN in general is likely to have been 
overdiagnosed in the trials because most carried out cervical cytology at intervals of 
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6-12 months rather than at the normal screening interval of 36 months. This means 
that the trials may have overestimated the efficacy of the vaccine as some of the 
lesions would have regressed spontaneously. 
3. Persistent HPV infection - The outcomes for HPV infection are difficult to interpret. 
Many trials diagnosed persistent infection on the basis of frequent testing at short 
intervals i.e. less than six months. This leaves uncertainty as to whether detected 
infections would clear or persist and lead to cervical changes. In the current Public 
Health England cervical screening programme, patients who are HPV positive but 
cytology negative are not retested for 12 months.(74) 
4. Differences between trial and real world populations - Most of the people in the 
trials were older than the 9-13 year olds who are typically offered vaccination. 
Efficacy in girls aged 9-13 has been estimated using immunobridging trials (where 
immune response levels are measured) rather than using clinical efficacy 
outcomes.(60) We do not know what level of antibody titres protect against cervical 
cancer and its precursors, or how long protection will last.(60) Similarly data on the 
outcomes for women older than 24 years are limited, and all trials apart from the 
Costa Rica Vaccine Trial (CVT) had exclusions on eligibility related to sexual 
history or history of genital warts or cervical disease, limiting the generalisability to 
catch-up vaccination populations.(36) HPV epidemiology varies globally. No 
efficacy studies were done in Africa.
5. Cross-protection and HPV-type substitution – There is uncertainty about whether 
the vaccine will provide cross-protection against oncogenic HPV-types not targeted 
by the vaccines. There is also a risk of substitution where a non-vaccine oncogenic 
HPV-type fills the void left by the reduction of an HPV type targeted by the 
vaccines.
6. Methodological considerations – Many trials included multiple underpowered 
subgroup analyses, which increase the chance of false positive findings. All trials 
except CVT reported relative rather than absolute effects, which tends to overstate 
efficacy, and none provided numbers needed to vaccinate. 
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V501-041
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monovalent 
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V501-005
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HPV-001
HPV-007
HPV-023PATRICIA
Konno
Zhu
VIVIANE
Legend: Trial sponsor
 GSK NCI & GSK
The study was sponsored and funded by 
NCI,  but it was done under an FDA 
investigational new drug application 
(IND),  for which the manufacturer has to 
function as sponsor.
Merck 
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Supplement 1. UK and US government information on HPV vaccination
Source Comment
NHS website, UK (1)
‘It helps protect them against cervical cancer, which is the most 
common cancer in women under 35 in the UK. The HPV vaccine is 
effective at stopping girls getting the types of HPV that cause most 
cervical cancers, and some other anal and genital cancers and cancers 
of the head and neck.’
‘Gardasil protects against 4 types of HPV: 6, 11, 16 and 18. Between 
them, types 16 and 18 are the cause of most cervical cancers in the UK 
(more than 70%)’. ‘Studies have already shown that the vaccine 
protects against HPV infection for at least 10 years, although experts 
expect protection to last for much longer.’
Public Health England 
HPV vaccination guide(2)
‘Girls who have the vaccine will significantly reduce their chance of 
getting cervical cancer.’
CDC, 6 reasons to get HPV 
vaccine for your child(3)
‘HPV vaccination is cancer prevention. HPV causes over 33,700 cases 
of cancer in men and women every year in the U.S. HPV vaccination 
can pr vent over 90% (31,200) of these cancers from ever developing 
by preventing the infections that cause those cancers.’
References
1. NHS. HPV vaccine - NHS: Department of Health; 2019 [Available from: 
https://www.nhs.uk/conditions/vaccinations/hpv-human-papillomavirus-vaccine/.
2. Public Health England. HPV vaccination guide. 2017.
3. CDC. 6 reasons to get HPV vaccine for your child: CDC; 2018 [Available from: 
https://www.cdc.gov/hpv/infographics/vacc-six-reasons.html.
Page 27 of 71
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
Supplement 2. Phase 4, observational and follow-up studies considering efficacy/ 
effectiveness outcomes
Study
Sponsor
Type 
of 
study
Country/ 
timeframe/ 
gender/ 
age/ size
Details Primary 
efficacy/ 
effectiveness 
outcome(s)
Study status
Results 
Which 
reasons for 
uncertaint
y does this 
address? 
CERVARIX
1 NCT005
34638
GSK
Phase 
IV 
trial
Finland
Oct 2007- 
Dec 2014
Male and 
female
12-15yrs
34206 
enrolled
Randomized 
non-blinded. 
Three 
groups- 
Cervarix 90% 
boys & girls 
vaccinated, 
10% Energix-
B ; Cervarix 
90% girls 
vaccinated, 
10% girls & 
100% boys 
Energix B; 
100% 
Energix-B
Effectiveness 
against 
incident 
genital 
infection with 
HPV 16/18 in 
females at 
18.5 years of 
age. 
Completed
Results published: Incident 
HPV infection, VE against 
HPV 16/18 incident infection 
varied from 89.2 to 95.2% 
across different birth cohorts 
in groups where some 
received Cervarix 
vaccination.(1)
None
2 NCT022
96255
Cancer 
Preventio
n and 
Research 
Institute, 
Italy
Phase 
IV 
study
Italy
Apr 2010 – 
Jul 2013 
(30 
months)
Female
25 yrs 
832 
enrolled
This study 
included a 
control group
Incident HR-
HPV 
infection, 
cytological 
abnormalities
Completed
Results published:
There was a reduction in 
abnormal cytology in the 
vaccinated group but this 
was not statistically 
significant.(2)
None due to 
the short 
follow-up, 
small study 
population, 
and the 
outcome.
3 NCT013
93470
Universit
y of 
Tampere 
(FinnMe
di Oy and 
GSK as 
collabora
tors)
Obser
vation
al 
cohort 
study
Finland
May 2011 
–Dec 2024 
(est.)
Female
16-19 yrs 
10,000 
(est.)
Following up 
Finnish 
participants 
of the GSK-
run 
PATRICIA 
trial, HPV-
008 is due to 
continue until 
2024. 
Estimated 
enrollment 
10,000. 
Includes a 
comparison 
against a 
non-
vaccinated 
cohort
CIN3+ Enrolling participants
Interim results published, 
follow-up of 4.5 to 10 years. 
Intention-to-treat VE against 
any CIN3+ 66% (95% CI 8, 
88).(3)
Longer 
follow-up 
and more 
stringent 
outcome of 
CIN 3+ but 
based on 
vaccination 
of a trial 
cohort not 
general 
population.
4 NCT009
29526
GSK
Follo
w-up 
of 
Konn
o
Phase 
III
Japan
Jun 2009 – 
Feb 2011
Female
20-25 yrs
752 
included
Follow-up of 
Konno study 
(initial study 
2 years) for 
additional 2 
years, non-
blinded. 
CIN1+ cases 
associated 
with HPV 16 
and/or HPV 
18
Completed
Results published: In TVC-
naïve group, vaccine efficacy 
regardless of HPV type to 
CIN3+ was 100% but 
insignificant confidence 
intervals (−417.0–100) and 
None- Too 
small, short 
follow-up, 
insignifican
t results for 
CIN3+ 
irrespective 
of HR-HPV 
type
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only two cases in control 
group.(4)
Note: any HR -HPV type – 
was a secondary outcome
5 Pollock 
et al
Independ
ent, 
funding 
from 
Chief 
Scientist 
Office 
grant
Obser
vation
al 
cohort 
study
Scotland
2008-May 
2013
Female
Aged 20-21 
in 2008-
2012
106,052
Registry 
based cohort 
study 
analysing 
colposcopy 
data of 
women born 
between 
1988-1992 
who entered 
cervical 
screening and 
were aged 
20-21 from 
2008-2012, 
comparing 
rates of 
CIN1, 2 and 
3 between 
those 
immunised 
and not 
immunised.
CIN1, CIN2 
and CIN3 
incidence rates 
per 1000 
person-years 
and relative 
risk reduction 
amongst those 
vaccinated.
Completed
RR of CIN3 for those 
receiving 3 doses adjusted 
for age, deprivation and 
cohort year 0.45 95%CI 
(0.35, 0.58) p<0.0001.
RR of CIN3 for those 
receiving 1 or 2 doses not 
statistically significant but 
small numbers.(5)
Considers 
CIN3 alone, 
and 
considers 
CIN3 
regardless 
of HPV 
type, 
considers 
women in 
Scottish 
national 
screening 
programme 
so usual 
rate of 
screening.
Authors 
acknowledg
e they could 
not adjust 
for whether 
participants 
stayed in 
school- 
those who 
did would 
have been 
part of 
catch-up 
vaccination 
cohort
6 Cameron 
et al
Obser
vation
al 
study
Scotland
Cervical 
screening 
samples 
from 2009-
2013
Female
Age 20-21 
at time of 
cervical 
screening
5,715 
women
HPV testing 
on cervical 
screening 
samples from 
2009-2013, 
prevalence of 
incident 
infection by 
HPV type
HPV type (16 
or 18; 31, 33 
or 45; other 
non-vaccine 
high risk types 
(35, 39, 51, 
52, 56, 58, 59, 
68) prevalence 
for those 
receiving three 
doses of 
Cervarix vs 
none, potential 
herd immunity 
with trends 
over time in 
those not 
vaccinated.
Decrease in HPV 16 and 18 
in vaccinated vs non-
vaccinated women 11.0% vs 
29.4%, adjusted OR 0.30 
95%CI (0.25, 0.35)
Annual prevalence of HPV 
16 and 18 decreased over 
time, 10. 1% (8.4, 12.2) in 
2009 vs. 28.8% 95%CI 
(26.7, 31) in 2013.
Prevalence of 31, 33 and 45 
decreased in vaccinated vs 
unvaccinated.
Prevalence of non-vaccine 
non-cross protective high-
risk HPV types significantly 
increased from 29.1%  
95%CI(26.9, 31.3) in 2009 to 
33.9% 95%CI(31.0, 36.8) in 
2013.
Prevalence of HPV 51 was 
marginally and non-
significantly increased in 
vaccinated compared to non-
vaccinated women.(6)
Uses 
incident 
infection. 
Raises 
concerns 
about 
potential for 
type 
replacement
.
7 Cruicksh
ank et al
Obser
vation
al 
Scotland
Colposcopy 
referrals 
Ecological 
study of 
women 
Referral 
criteria, 
positive 
Completed Ecological 
study so  
not causal 
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ecolo
gical 
study
from 2008-
2014 
Female
Age 20 or 
21 at time 
of 
colposcopy 
and born 1 
Jan 1985 or 
later
7,372 
women
referred for 
colposcopy 
and 
outcomes.
predictive 
value
of colposcopy, 
default rates, 
and rates of 
cervical 
biopsies and
treatments.
Reduction in the proportion 
of those  referred for 
colposcopy due to abnormal 
cytology,  91% in 2008-09 to 
90.3% in 2013-14, p=0.03
Reduction in rates of CIN2+ 
of those referred for 
colposcopy 39.21% in 2008-
09 and 25.81% in 2013-
14.(7)
and results 
not linked 
to 
immunisati
on status. 
Uses usual 
frequency 
of testing as 
includes 
results from 
cervical 
screening 
programme.
8 Palmer et 
al
Health 
Protectio
n 
Scotland
Obser
vation
al 
study
Scotland
Smear test 
results aged 
20 of 
women 
born 
between 1 
Jan 1988 
and 5 Jun 
1996
138,692 
women
Retrospective 
population 
study of 
results on 
first cervical 
screening 
linked to 
immunisation 
status and 
date of birth
Cytology and 
histology 
findings on 
cervical 
screening
Completed
For fully immunized women, 
first vaccinated aged 12-13, 
vaccine effectiveness against 
CIN3+ due to any HPV type 
86% 95%CI(75, 92). For 
women first vaccinated aged 
17, vaccine effectiveness 
against CIN3+ 45% 
95%CI(17, 64)(8)
Observation
al study so 
cannot 
establish 
causality, 
see main 
text for 
more 
information
GARDASIL
8 NCT000
92534/ 
Nordic 
Cancer 
Registry 
Study/ 
V501-
015
Merck
Follo
w-up 
of 
FUTU
RE II
Post-
marke
ting 
comm
itment 
(EMA
, US 
FDA)
Denmark, 
Norway, 
Sweden, 
Iceland
OrIginal 
study Jun 
2002 – Jul 
2007, 2 
extension 
studies 
until Mar 
2017
Female
16-23 yrs
12167 
enrolled
First 
extension 
study V501-
015-10
Second 
extension 
study V501-
015-20
Registry 
based follow-
up
CIN2+ due to 
HPV 16/18
Completed.
Preliminary data published in 
conference abstract in 2013.
No cases in vaccinated 
cohort at 9 years but figures 
not given for placebo cohort 
or for CIN due to any 
oncogenic type.(9)
Unknown, 
as full 
results not 
yet 
published, 
and not 
clear 
whether 
figures for 
any 
oncogenic 
types will 
be 
presented. 
Unlikely 
due to 
composite 
endpoints 
and short 
follow-up
9 NCT000
92547 
Adolesce
nt 
Sentinel 
Cohort 
Study/ 
V501-
018
Merck
Immu
nogen
icity 
trial
Phase 
III
Post-
marke
ting 
comm
itment 
(EMA
, US 
FDA)
Columbia, 
Denmark, 
Mexico, 
Norway, 
Portugal, 
Spain, 
Taiwan, 
Thailand, 
UK, US
Oct 2003 – 
Jun 2015
Male and 
female
9-15 yrs 
1781 
enrolled
Extended 
with a 
secondary 
outcome to 
assess 
effectiveness 
up to 126 
months. 
Comparing 
early (EVG) 
and catch-up 
(CVG) 
vaccination 
groups.
Primary 
outcome was 
regarding 
immunogenici
ty.
Completed.
Preliminary results have 
been presented up to 96 
months.(10)
Secondary outcome looking 
at effectiveness- CIN1+ due 
to HPV6/11/16/18 or 
persistent infection of 4 
months duration. 
EVG 2 cases of persistent 
HPV 16 infection out of 256 
girls. In CVG, 2 cases of 
HPV 16 persistent infection, 
4 cases of HPV-18 persistent 
infection, 1 case of HPV-18 
CIN1. Small numbers for 
effectiveness outcomes. 
Considers 
girls of 
target 
vaccination 
age 
however  
multicountr
y study – 
small 
numbers at 
country 
level; 
combined 
endpoints, 
small 
numbers for 
effectivenes
s outcomes. 
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1
0
NCT010
77856 
Vaccine 
Impact in 
Populatio
n study/ 
V501-
033
Merck 
(collabor
ators: 
Danish 
Cancer 
Society 
Union for 
Internatio
nal 
Cancer 
Control 
Cancer 
Registry 
of 
Norway 
Karolinsk
a 
Institute)
Obser
vation
al 
cohort 
study
Post-
marke
ting 
comm
itment 
(EMA
, US 
FDA)
Norway, 
Sweden 
and 
Denmark
May 2007- 
Dec 2014
Female
18-45 yrs
54,516 
enrolled
Registry 
based 
incidence 
rates of HPV-
related 
genital 
disease in 
pre-vaccine 
era (2004-
2006) and 
post 
vaccination 
periods 
(2007-2011)
Incidence of 
CIN1+, 
incidence of 
HPV 
6/11/16/18 
and other than 
16/18 HR -
HPV type 
related 
CIN2+, 
incidence of 
HPV-related 
female genital 
diseases (incl. 
vulvar and 
vaginal cancer 
and their high 
grade 
precursors), 
prevalence of 
HPV 
6/11/16/18 
and other than 
16/18 HR -
HPV type 
infection
Completed. 
Results obtained through 
FOI request through EMA, 
not published.(11)
Incidence of CIN2+ 
increased in Denmark and 
Sweden across all ages 
during the study period. In 
Danish data, When stratified 
by vaccination status, 
incidence of CIN2+ showed 
a significant decrease in the 
youngest age group with 
high vaccination coverage. 
No appreciable changes in 
rates of cervical cancer in 
any of the countries during 
the follow-up period.
Large study 
cohort but 
short 
duration 
and use of 
combined 
endpoints
1
1
NCT015
44478/V
501-110
Merck
Phase 
IV 
study
Japan
Nov 2011 
to Aug 
2016
Female
16-26 yrs
1,030 
participants 
enrolled
Open label 
descriptive 
study
Combined 
incidence of 
CIN2+ related 
to HPV 
6/11/16/18 up 
to month 48 
post-
vaccination
Completed. 
Results not published
Unknown 
but unlikely 
given use of 
combined 
endpoint
1
2
Rana et 
al
Grant 
sponsors:
Finnish 
Cancer 
Organizat
ions and 
Nordic 
Cancer 
Union, 
Merck& 
Co. Inc., 
GSK 
Biologica
ls 
Cohor
t 
cancer 
registr
y-
based 
follow
-up
Finland
2007-2011
Female
16 to 17 yrs 
(at the time 
of 
vaccination
)
866 
vaccinated 
subjects, 
861 
placebo 
subjects 
(50% cross-
vaccinated 
in 2007), 
15,719 
unvaccinate
d reference 
cohort.
Four year 
passive 
follow-up of 
Finnish 
cohort from 
FUTURE II 
(involved in 
active follow-
up from 
2002-2007). 
Incidence of 
CIN3+ 
Completed. 
Results published: Incidence 
rates of CIN3 for the three 
groups were 0/100,000, 
87.1/100,000 and 
93.8/100,000. 
“We identified zero cases of 
CIN3 or ICC in the 
HPV6/11/16/18 cohort, three 
cases of CIN3 in the original 
placebo cohort (with or 
without cross-vaccination) 
and 59 CIN3 and 3 ICC 
cases in the unvaccinated 
reference cohort.”
(note: first two CI wide, the 
third one tight)(12) 
Some 
evidence 
for more 
stringent 
endpoint of 
CIN3+ 
regardless 
of HPV 
type, 
however 
short 
follow-up 
1
3
NCT000
90220/ 
V501-
019/ 
FUTURE 
III
Long-
term 
follow
-up 
study
Colombia
Jun 2004 – 
Nov 2015
Female
24-45 yrs 
(age at 
No control 
group. 
Included 
early 
vaccination 
group and 
HPV6/11/16/1
8 related 
CIN1+ or 
genital warts; 
and HPV 
16/18 CIN2+
Completed.
Results of interim analysis to 
Year 6 post-start of base 
Some 
supporting 
evidence 
for 
effectivenes
s in older 
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Merck
vaccination 
of EVG), 
29-50 yrs 
(age at 
vaccination 
of CVG)
3819 
enrolled in 
original 
study 
(contribute 
to analysis 
of first 4 
years), rest 
of analysis 
just for 
Colombia 
cohort 1360 
participants 
(1335 
vaccinated)
.
catch-up 
vaccination 
group. 
Extension 
study of 
FUTURE III 
trial 
including 
women from 
Colombia 
study sites to 
look at 
safety, 
effectiveness 
and 
immunogenic
ity.
study published, details of 
Year 8 analysis in 
conference abstract, further 
analysis planned at  Year 10.
Secondary outcomes of non-
HPV 6/11/16/18 related 
genital warts or cervical 
dysplasia, and of non-HPV 
16/18-related CIN2+
At Year 6, no new cases 
since base study of 
HPV6/11/16/28 CIN1+ or 
genital warts. 2 cases of HR 
non-vaccine HPV type 
CIN2+ in EVG full-analysis 
population.(13) 
At Year 8, no cases of 
HPV6/11/16/18 CIN1+ or 
genital warts in EVG.(14) 
women and 
looking at 
cross-
protection 
but short 
follow-up, 
no control 
and results 
reported 
only for the 
combined 
endpoint
1
4
NCT008
34106
/ V501-
041
Merck
Phase 
III
China
Dec 2008- 
Sept 2016 
(78 months 
follow-up)
Female
20-45 yrs
3006 
enrolled 
Randomised 
placebo-
controlled 
blinded trial 
of Gardasil
Persistent 
HPV 
6/11/16/18 
infection or 
related genital 
disease (up to 
month 30); 
CIN2+ (up to 
month 78)
Completed.
No results published or 
posted on clinicaltrials.gov
Unlikely- 
although 
placebo-
controlled, 
using 
combined 
endpoints, 
small 
numbers 
and short 
follow-up
1
5
NCT026
53118/ 
V503-
021
Merck
Obser
vation
al 
study
(Regis
try-
based 
extens
ion of 
protoc
ol 
V503-
001)
Denmark, 
Norway, 
Sweden
Original 
study 
period-Sept 
2007- July 
2016 (up to 
54 months)
Extension 
Jan 2016- 
Jan 2024
Female
16-26 yrs at 
time of 
vaccination
4453 (est.)
Long-term 
observational 
follow-up of 
participants 
from Nordic 
countries of 
original 
V503-001 
trial of 
Gardasil 9 vs. 
Gardasil. 
Gardasil 
subjects were 
offered cross-
vaccination 
with Gardasil 
9.
Combined 
incidence of 
HPV 
16/18/31/33/4
5/52/58 
related CIN2+ 
up to 16 years 
after 
vaccination in 
V503-001 
base study 
Ongoing, not recruiting. May 
address 
long-term 
efficacy 
given 
length of 
follow-up 
however 
unlikely as 
combined 
endpoints 
and small 
study 
numbers 
1
6
NCT029
34724
Oslo 
Universit
y 
Hospital
(Collabor
ator: 
Universit
y 
Hospital, 
Obser
vation
al 
study
Norway
Nov 2016- 
est Dec 
2018
Female 
born in 
1997
18-20 yrs
317 
participants
. Vaginal and 
oral HPV 
6/11/16/18 
prevalence in 
vaccinees and 
non-vaccinees. 
Ongoing, not recruiting None, small 
size and 
looking at 
vaccine 
type HPV 
incidence 
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Akershus
)
1
7
Baldur-
Felskov 
et al.
Funding: 
Mermaid 
Project 
(MERM
AID2)
Obser
vation
al 
cohort 
study
Denmark
Oct 2006- 
March 
2012
Female
Included all 
girls born 
in Denmark 
from 1989 
to 1999 
399,244 
women
Information 
on 
vaccination 
status from 
registries, 
linked to 
information 
on cervical 
lesions.
Risk of 
atypia+; 
CIN2+
  and CIN3+ 
in vaccinated 
vs. 
unvaccinated
Completed.
Results published:
Birth cohorts 1989-1990 
statistically significant 
reduced risk of atypia+, 
reduced risk of CIN2+ but 
not statistically significant. 
Birth cohorts 1991-1994 
statistically reduced risk of 
atypia+ and CIN2+. No 
events in birth cohort 1997-
1999.(15) 
Some 
supporting 
evidence 
for girls in 
target 
vaccination 
group but 
follow up 
too short 
with low 
incidence 
rates and 
use of 
combined 
endpoints
1
8
NCT031
05856
FASTER
-Tlalpan 
Study 
(FASTE
R)
Instituto 
Nacional 
de Salud 
Publica, 
Mexico
Phase 
IV
Cerva
rix
Garda
sil
Mexico
Jan 2017 – 
unclear (10 
years 
duration)
Female
25-45 Yrs
18,000 
(est.)
Three 
groups- 
bivalent 
vaccine +HR-
HPV 
screening, 
quadrivalent 
+ HR HPV 
screening, 
HR HPV 
screening 
alone. 
2-dose HPV 
vaccination
Incidence 6-
month 
persistent 
infection of 
HPV 16 or 
HPV 18
Secondary 
outcome 
CIN2+
 
Ongoing, not recruiting May help 
answer 
questions 
about cross-
protection 
as 
comparing 
two 
vaccines, 
included 
control 
group. May 
help answer 
uncertaintie
s regarding 
disease 
outcome 
regardless 
of HPV 
type. May 
provide 
information 
on longer 
term 
follow-up.
1
9
Drolet et 
al.
Funding: 
The 
Canadian 
Institutes 
of Health 
Research
Syste
matic 
revie
w and 
meta-
analys
is of 
popul
ation 
based 
time-
trend 
ecolo
gical 
studie
s.
20 eligible 
studies 
conducted 
in 8 high-
income 
countries 
(US, UK, 
Australia, 
New 
Zealand, 
Canada, 
Sweden, 
Denmark, 
Germany).
Studies 
looked at 
period from 
1985 to 
2012
Male and 
female
Study 
participants 
Included 
population-
based and 
clinic-based 
studies, some 
looked at 
herd-
immunity 
post-female 
vaccination 
programmes.
Assessed 
prevalence of 
HPV 
infection, 
genital warts 
and cervical 
dysplasia pre 
and post-
immunization 
screening 
programmes. 
Completed. 
Results published
Evidence from one study 
(Brotherton) of a reduction 
in prevalence of CIN2+ in 
girls <18 years three years 
after vaccination programme 
introduction.(16) 
Ecological 
studies so 
not directly 
addressing 
the 
uncertaintie
s raised but 
provides 
supportive 
evidence 
for impact 
in general 
population.
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ranged 
from 13-39
Variable 
sample 
sizes
Sources: The information on type of study, country, duration, participants and primary efficacy objectives was collected 
from clinicaltrials.gov on 13-14th June 2017.
Results were sourced from published studies
* final report received from the EMA (FOI request)
Abbreviations: EVG=Early Vaccination Group, CVG= Catch-up Vaccination group, HR-HPV type = high risk HPV type
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Database Search strategy
Medline 
search criteria 
(02.01.15, 
then re-run on 
10.05.16 and 
30.07.18):
‘exp papillomavirus vaccines/’ OR ‘hpv vaccin*.mp’ OR 
‘human papillomavirus vaccin*.mp’  = 8,957
AND efficacy.mp (698,216) = 1,107
Limit to ‘clinical trial-all, clinical trial, controlled clinical trial, 
meta-analysis, randomised controlled trial, systematic reviews 
= 204
Limit to English Language = 197
Embase 
search 
criteria: 
(02.01.15, 
then re-run on 
10.05.16 and 
30.07.18)
(hpv/ OR hpv) AND vaccin* = 15,007
AND efficacy = 2,787
limit to randomised controlled trial, controlled clinical trial, 
meta analysis, Cochrane review, systematic review And 
English language
= 318
Additional 
searches
Clinicaltrials.gov: ‘hpv vaccine’ limited to phase 2, 3, and 4 
trials
EU Clinical Trials Database: ‘hpv vaccine’
Search of GSK and Merck websites for registered trials
Additional papers were found through reviewing references of 
papers found and search updates from Embase and Medline.
We included the results of one trial, V501-041, that was 
published after our last search.(1) A further search for 
observational and Phase 4 trials was run on 06.04.17. One 
study, Palmer et al, which was published after this search was 
included.(2)
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Supplement 4. HPV systematic reviews and meta-analyses
Paper Systematic 
review or 
Meta-analysis
Focus Included trials Comments including any notable findings and 
problems with the review
Schmiedeska
mp et al 
2006(1)
Systematic 
review
Pharmacology, 
efficacy, safety, 
tolerability, and 
pharmacoeconomi
cs
Brown 04 (post-hoc analysis of 
Phase I trials), Koutsky 02 (V501-
005), Harper 04 (HPV-001), Villa 
05 (V501-027), FUTURE I (interim 
results), FUTURE II (interim 
results)
 Early review so limited number of trials 
included and used interim results
FUTURE II 
STUDY 
GROUP 
2007(2)
Meta-analysis Efficacy of 
Gardasil in 
Women with
Virological 
Evidence of HPV 
Infection
FUTURE I, FUTURE II  Only two Gardasil trials
 Post-hoc analysis
La Torre et al 
2007(3)
Systematic 
review & meta-
analysis
Persistent six-
month cervical 
infection with 
HPV 16/18
Villa 06 (V501-007), Harper 06 
(HPV-001), Mao 06 (V501-005), 
Brown 04, Paavonen 07 
(PATRICIA)
 Limited to five trials
 Included evidence from monovalent vaccine
 Did not discuss limitations of six-month 
persistent infection
Rambout et al 
2007(4)
Systematic 
review & Meta-
analysis
Main outcome 
vaccine HPV-type 
CIN2+
FUTURE II, FUTURE I, HPV-001, 
V501-005, PATRICIA (Paavonen 
07), V501-007 (Villa 05, Villa 06)
 Acknowledged short trial length, trial 
heterogeneity, high loss to follow up and high 
rates of participant exclusion in sub-groups
Ault et al 
2007(5)
Meta-analysis Gardasil efficacy 
against CIN2+
V501-001, V501-007, FUTURE I, 
FUTURE II
 Combined results from monovalent vaccine
 Mean follow-up three years
Barr et al Meta-analysis Gardasil efficacy FUTURE I, FUTURE II, V501-  Used ITT population but initial trial 
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2008(6) in North America 
in sexually active 
women
005, V501-007, V501-016 
(immunogenicity trial)
recruitment restricted number of previous 
partners
Harper et al 
2008(7)
Meta-analysis Impact of 
Cervarix on 
subsequent HPV-
16/18 infection
and cervical 
disease in women 
15–25 years of 
age
HPV-007, PATRICIA- interim 
analysis
 Used CIN2+ lesion case assignment based on 
previous history of persistent HPV infection
Joura et al 
2008(8)
Meta-analysis Correlating 
immune response 
and efficacy
FUTURE I, FUTURE II  No immune correlate with vaccine efficacy 
found
Perez et al 
2008(9)
Meta-analysis Safety, 
immunogenicity 
and efficacy of 
Gardasil in Latin 
America
FUTURE I, FUTURE II, V501-
007, V501-018, V501-016 
(immunogenicity)
Tay et al 
2008(10)
Meta-analysis Safety, 
immunogenicity 
and efficacy of 
Gardasil in Asia-
Pacific region
FUTURE I, FUTURE II
Brown et al 
2009(11)
Meta-analysis Gardasil efficacy 
on non-vaccine 
HPV in HPV-
naïve women
FUTURE I, FUTURE II  Used combined surrogate outcome of CIN1+
Damm et al Systematic Efficacy and cost- Did not specify which trials were  Labelled as systematic review but no 
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2009(12) review effectiveness considered evidence of this in analysis
Kjaer et al 
2009(13)
Meta-analysis Efficacy of 
Gardasil against 
CIN2+ due to 
vaccine-HPV 
types
V501-007, FUTURE I, FUTURE II  Combined lesions due to HPV 6 and 11 
which are not known to be carcinogenic
Lazcano-
Ponce et al 
2009(14)
Meta-analysis Impact of 
Gardasil in 
Mexican women
Post-hoc analysis of FUTURE I and 
FUTURE II
 Combined surrogate outcome of 
HPV6/11/16/18 CIN1+
Majewski et al 
2009(15)
Meta-analysis Impact of 
Gardasil in 
European women 
Efficacy against 
CIN and EGL by 
HPV6/11/16/18 in 
PPE, efficacy 
against CIN and 
EGL due to any 
HPV type in naïve 
group
V501-007,
FUTURE I,
FUTURE II,
V501-016 (immunogenicity study)
Medeiros et al 
2009(16)
Systematic 
review and 
Meta-analysis
Efficacy of 
Cervarix and 
Gardasil against 
all genital lesions 
in ITT sub-group
HPV-001 (Harper 06), CVT 
(Hildesheim 07), PATRICIA 
(Paavonen 07), V501-005 (Mao 
06), FUTURE I (Garland), 
FUTURE II (FUTURE II)
 Reported they found inconsistency and 
heterogeneity among the trials
Olsson et al 
2009(17)
Meta-analysis Gardasil efficacy 
in women with 
previous HPV 
V501-007,  FUTURE I, FUTURE 
II
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infection
Wheeler et al 
2009(18)
Meta-analysis Oncogenic non-
vaccine HPV 
types in sexually 
active women
FUTURE I, FUTURE II  Pre-specified analysis non-vaccine CIN1+ 
(combined surrogate outcome)
Dillner et al 
2010(19)
Meta-analysis Gardasil efficacy 
against low-grade 
cervical and 
genital lesions
FUTURE I, FUTURE II  Focus on CIN1 and non-cervical genital 
lesions so less relevant to cervical cancer
Munoz et al 
2010(20)
Meta-analysis Gardasil efficacy 
against all HPV-
associated genital 
disease
FUTURE I, FUTURE II
Ault et al 
2011(21)
Meta-analysis Quadrivalent 
efficacy against 
AIS
FUTURE I, FUTURE II  Only 25 positive cases of AIS in two trials
Lu et al 
2011(22)
Systematic 
review and 
Meta-analysis
Efficacy and 
safety. Primary 
endpoint CIN2+
V501-005 (Koutsky, Mao 06), 
HPV-001 (Harper 06), HPV-007 
(Harper 04), V501-007 (Villa 05, 
Villa 06), FUTURE I (Garland 07, 
Brown 09, Wheeler 09), FUTURE 
II (Future II Study Group, Brown 
09, Wheeler 09), FUTURE III 
(Munoz 09), PATRICIA (Paavonen 
07, Paavonen 09)
 Included Monovalent HPV-16 vaccine trial
 Seven trials included
Haupt et al 
2011(23)
Impact of an 
HPV6/11/16/18 
L1 viruslike 
particle vaccine 
Gardasil efficacy 
against HPV16/18 
CIN2+ in women 
with HPV16/18 
FUTURE I, FUTURE II  No impact on incidence of HPV 16/18 
CIN2+ if already existing infection
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on progression 
to cervical 
intraepithelial 
neoplasia in 
seropositive 
women with 
HPV16/18 
infection
DNA positivity 
prior to 
vaccination
Joura et al 
2012(24)
Effect of the 
human 
papillomavirus 
(HPV) 
quadrivalent
vaccine in a 
subgroup of 
women with 
cervical and
vulvar disease: 
retrospective 
pooled analysis 
of trial
data
Impact of 
Gardasil on a 
subgroup with 
vulvar and 
cervical disease
FUTURE I, FUTURE II
Malagon et al 
2012(25)
Systematic 
review and 
Meta-analysis
Cross-protection 
against CIN2+ 
and 6 month 
persistent 
infection due to 
non-vaccine HPV 
types
FUTURE I, FUTURE II, 
PATRICIA, HPV-001/007/023
 Higher cross-protection for Cervarix but 
admitted this could be due to difference in 
study design.
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Clark et al 
2013(26) 
Meta-analysis Gardasil efficacy 
in Black women
FUTURE I, FUTURE II
Tomljenovic 
et al 2013(27)
Systematic 
review
Comparison of 
efficacy and 
safety of Cervarix 
and Gardasil
FUTURE I, FUTURE II, V501-
007, 
 No meta-analysis done
 Raised concerns about use of surrogate 
markers, selective reporting of results.
Couto et al 
2014(28)
Systematic 
review and 
meta-analysis
Impact of catch-
up vaccination on 
girls aged 16+ 
Monovalent HPV-16 vaccine, 
PATRICIA, FUTURE III, HPV-
001/007/023, V501-007, FUTURE 
I, FUTURE II
 Acknowledges important differences in 
inclusion criteria for the different trials, 
limiting generalizability of the findings to the 
target population for catch-up vaccination
 Borderline protective effect of a HPV catch-
up vaccination on all CIN2+, with a pooled 
RR of 0.80 (95% CI: 0.62-1.02) for a follow-
up period of 4 years
Delere et al 
2014(29)
Systematic 
Review and 
Meta-analysis
Short- and long-
term efficacy 
FUTURE I, FUTURE II, HPV-
001/007/023, CVT, Konno, 
PATRICIA, V501-007
 Based on just seven trials
 Combined CIN2+ associated with any HPV 
type and vaccine types in the same analysis
Miltz et al 
2014(30)
Systematic 
review and 
Meta-analysis
Women with 
evidence of prior 
exposure, CIN3+
PATRICIA (Lehtinen 12), 
FUTURE III (Castellsague), Olsson 
2009 meta-analysis, Joura 2007 
(non-cervical outcomes)
 No evidence that vaccination prevents 
vaccine type HPV cervical pre-cancer in 
women with evidence of prior HPV exposure
 Reviewers did not separate women with 
seropositive status (indicating past infection) 
from those DNA positive (indicating on-
going infection)
DiMario et al 
2015(31)
Systematic 
review and 
Meta-analysis
Comparison of 
Cervarix and 
Gardasil
PATRICIA, Konno, FUTURE I, 
FUTURE II, HPV-001/007
 Noted a difference in efficacy between the 
two vaccines in the TVC-naïve cohort against 
CIN2+ due to any HPV type (higher efficacy 
with Cervarix).
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 The authors requested single patient data 
from both GSK and Sanofi Pasteur MSD but 
these requests were not met.
 Noticed significant heterogeneity between the 
trials, that data were often “differently and 
poorly reported” and length of follow-up was 
insufficient.
 Only considered five trials
Kreimer et al 
2015(32)
Meta-analysis Cervarix efficacy 
with 1 vs. 2 vs. 3 
doses
PATRICIA, CVT  Post-hoc analysis
 Primary endpoint incident infection (not 
considered adequate surrogate endpoint) 
Angioli et al 
2016(33)
Systematic 
review
Vaccine efficacy 
and safety
HPV-001/007/023, V501-007, 
PATRICIA, CVT, FUTURE I, 
FUTURE II, Gardasil 9 trial
 Only considered seven trials
 Did not discuss the issues raised by the 
heterogeneity of the trials.
Skinner et al 
2016(34)
Systematic 
review
Efficacy of 
Cervarix
HPV-001/007/023, PATRICIA, 
CVT, VIVIANE, Konno, Zhu
 Paper funded by GSK
 Discussed challenges of proving cross-
protection as many lesions contained multiple 
HPV types
Tota et al 
2017(35)
Meta-analysis Risk of type-
replacement with 
Cervarix
PATRICIA, CVT  Looked at incident infection
 Only looked at data from two trials
Haghshenas et 
al 2017(36)
Meta-analysis Efficacy against 
CIN1+
V501-005 (Monovalent HPV-16 
vaccine, Mao), Perex meta-analysis 
(see above), 
 Looked at combined surrogate endpoint of 
CIN1+
 Did not include all relevant studies
Mousavi et al 
2017(37)
Meta-analysis Efficacy against 
persistent HPV 
infection
V501-007, V501-027, HPV-001, 
PATRICIA (Paavonen 07), V501-
005 (monovalent HPV-16 vaccine), 
Perez meta-analysis (see above), 
Majewski meta-analysis (see above)
 Did not include all relevant studies
 Did not take heterogeneity into account
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WHO 
Position Paper 
2017 (38)
Systematic 
review
Efficacy, and 
safety
FUTURE I, FUTURE II, V501-
007, HPV-001/007/023, PATRICIA 
(Interim analysis), Schiller 12 
review
 Acknowledge that definition of persistent 
infection of six months is not universally 
accepted
 ‘Current evidence suggests the 3 licensed 
HPV vaccines have relatively similar 
effectiveness in preventing cervical cancer’- 
no trials have shown impact on cervical 
cancer rates.
 ‘WHO recommends all countries proceed 
with nationwide introduction of HPV 
vaccination’
 ‘Low confidence of scientific evidence that 
HPV vaccination provides long term 
protection’
Arbyn et al 
2018(39)
Cochrane 
Systematic 
review and 
Meta-analysis
Efficacy against 
CIN2+ and 
CIN3+ for 
vaccine-type HPV 
and irrespective of 
HPV type
V501-005 (monovalent HPV-16 
vaccine), HPV-001/007/023, 
Konno, PATRICIA, CVT, 
VIVIANE, Zhu, V501-007, 
FUTURE I, FUTURE II, FUTURE 
III, V501-027
 Included all efficacy trials
 Focussed on CIN2+ but did not discuss the 
concerns with this surrogate marker  
 Did not discuss the issue of type-replacement
 Acknowledged that there was trial 
heterogeneity and that this affected efficacy
 Considered the results of the HPV-16 
monovalent vaccine trial which we have 
excluded
 For CIN3+ in HPV-naïve women included 
results from non-blinded follow-up of Konno
 For CIN3+ in women regardless of HPV 
status did not acknowledge restrictions on 
trial eligibility which mean women in trials 
likely less HPV exposure than general 
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population
 Did not comment on the small remaining 
number of participants in the trials used as 
evidence of prolonged vaccine efficacy.
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Supplement 5. Efficacy against CIN3/AIS in HPV-naïve women 
 
Supplement 5 Footnote: We have included the Munoz meta-analysis of FUTURE I and 
FUTURE II as it presents outcomes not given in the original trial papers.(48, 49) FUTURE I 
only gave results for CIN3 and AIS due to HPV6/11/16/18 combined, in both FUTURE I and 
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(13, 
63.2)
Gard
asil / 
Meta-
analy
sis of 
FUT
URE 
I and 
FUT
URE 
II
Mu
noz 
10(
56)
Nega
tive 
to 14 
HPV 
types 
popu
latio
n AIS 0/4616 3/4680 100% (<0 
, 100)
AIS 0/4616 3/4680 100% 
(<0, 
100)
FUT
URE 
II
FU
TU
RE 
II 
Stu
dy 
Gro
up(
49)
Per-
proto
col 
susce
ptibl
e 
popu
latio
n
CIN3 1/5305 29/5260 97 (79, 
100)
Results not 
given
Results 
not 
given
Results 
not 
given
Result
s not 
given
FUT
URE 
II
FU
TU
RE 
II 
Stu
dy 
Gro
up(
49)
Per-
proto
col 
susce
ptibl
e 
popu
latio
n
AIS 0/5305 1/5260 100 (<0, 
100)
Results not 
given
Results 
not 
given
Results 
not 
given
Result
s not 
given
Page 48 of 71
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
FUTURE II papers results for CIN3+ due to any HPV type were only given for ITT 
subgroup.
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Supplement 6. Vaccine efficacy against 12-month persistent infection in HPV-naïve 
women 
12-month persistent infection due 
to HPV 16/18
12-month persistent infection due 
to any oncogenic type
Vaccine/Trial Paper Subgroup
Number 
with 
outcome/ 
vaccinate
d cohort
Number 
with 
outcome/ 
placebo 
cohort
VE = 
Vaccine 
Efficacy 
(95%CI
) p-
value 
where 
given
Number 
with 
outcome/ 
vaccinate
d cohort
Number 
with 
outcome/ 
placebo 
cohort
VE = 
Vaccine 
Efficacy 
(95%CI
) p-
value 
where 
given
Cervarix/ 
Konno
Konno 
Jul 
10(27)
TVC-E 0/406 9/411 100% 
(47.4, 
100) 
p=0.003
7
19/443 37/441 50.1% 
(9.8, 
73.2) 
p=0.013
Cervarix/ Zhu Zhu 
17(45)
ATP-E 1/2425 32/2455 96.9% 
(81.1, 
99.9)
192/2703 215/2714 10.4% (-
9.3, 
26.7)
Cervarix/ 
PATRICIA
Szarewsk
i 12(33)
TVC 
stratified by 
HPV 16/18 
PCR 
negative and 
seronegative
51/7844 341/7854 85.3% 
(80.0, 
89.5)
Not given Not 
given
Not 
given
Cervarix/ 
PATRICIA
Paavone
n 09(29)
ATP-E Not given Not given Not 
given
549/7509 760/7488 28.9% 
(20.1, 
36.8) 
p<0.000
1
Cervarix/ 
HPV-023
Naud 
14(25)
ATP-E 0/193 10/175 100% 
(61.4, 
100)
36/179 36/158 12.9% (-
42.3, 
46.7)
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Supplement 7. Results from trials testing cross-protection against non-
vaccine HPV types
Statistically significant results given in bold
Vaccine Trial, 
Sub-group, 
Outcome
HPV 
type
Number with 
outcome/ 
vaccinated 
cohort
Number 
with 
outcome/ 
placebo 
cohort
VE = 
Vaccine 
Efficacy 
(95%CI) 
31 21/2525 39/2546 45.7% 
(8.2, 68.6)
33 8/2596 13/2645 37.3% (-
51.4, 75.3)
35 11/2593 13/2631 14.1% (-
94.0, 62.5)
52 60/2456 51/2505 -20.0% (-
74.9, 17.4)
58 23/2551 22/2595 -6.3% (-
92.4, 41.1)
39 24/2528 23/2581 -6.5% (-
90.2, 40.2)
45 8/2573 17/2622 52.0% (-
9.8, 80.4)
59 17/2576 10/2637 -74.0% (-
295.1, 
20.1)
68-73 19/2519 18/2576 -7.9% (-
108.1, 
43.8)
51 57/2453 36/2539 -63.9% (-
150.7, -8.2)
56 22/2524 30/2564 25.5% (-
29.2, 57.5)
CVT(1) Herrero et 
al, 11 
supplementary 
analysis,
ATP,
12 month 
persistent 
infection
66 32/2521 33/2565 1.3% (-
61.1, 39.6)
31 30/7295 136/7309 78.1% 
(67.2, 85.7)
33 38/7426 59/7404 35.8% 
(1.9, 58.5)
35 37/7468 26/7462 -42.6% (-
145.2, 
16.0)
Cervarix
PATRICIA 
Wheeler et al 12- 
supplementary 
analysis(2), 
ATP,
12 month 
persistent 
infection 52 200/7185 205/7134 3.0% (-
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32
33
34
35
36
37
38
39
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41
42
43
44
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46
47
48
49
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51
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53
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18.5, 20.6)
58 83/7411 54/7403 -54.1% (-
121.3, -8.1)
39 86/7322 86/7322 -0.2% (-
36.7, 26.6)
45 13/7485 32/7445 59.6% 
(20.8, 80.5)
59 27/7425 20/7422 -35.2% (-
154.3, 
26.9)
68 76/7344 75/7321 -1.1% (-
41.1, 27.5)
51 149/7089 192/7061 22.8% 
(3.8, 38.1)
56 104/7357 91/7343 -14.4% (-
53.3, 14.5)
66 92/7307 92/7266 0.4% (-
34.5, 26.2)
31 10/2073 29/2090 65.8% 
(24.9, 85.8)
33 12/2105 9/2094 -32.0% (-
275.2, 
51.5)
35 11/2112 17/2101 36.2% (-
50.8, 74.3)
52 54/2060 56/2058 4.9% (-
44.0, 37.2)
58 24/2098 19/2092 -25.3% (-
151.0, 
35.5)
39 34/2097 26/2078 -28.8% (-
130.7, 
27.1)
45 9/2106 30/2088 70.7% 
(34.2, 88.4)
59 22/2105 21/2083 -3.0% (-
104.0, 
47.9)
68 31/2084 33/2085 7.0% (-
61.3, 46.5)
51 48/2071 42/2072 -13.6% (-
80.6, 28.3)
56 28/2100 30/2081 8.4% (-
63.6, 48.9)
VIVIANE(3),
ATP,
6 month persistent 
infection
66 45/2089 49/2080 9.2% (-9.3, 
24.4)
31 3/2671 16/2676 81.2% 
(34.4, 96.5)
Zhu(4)
ATP-E, 12 month 
persistent 33 8/2663 9/2675 10.6% (-
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161.2, 
70.0)
35 11/2686 9/2695 -22.9% (-
235.5, 
53.7)
52 70/2553 63/2569 -12.4% (-
60.5, 21.2)
58 15/2656 18/2661 16.4% 
(−75.8, 
60.8)
39 15/2641 22/2664 −14.8% 
(−113.6, 
37.9)
45 5/2674 2/2694 −152.3% 
(−2549.9, 
58.7)
59 7/2694 2/2687 −250.2 % 
(−3355.0, 
33.3)
68 12/2659 12/2675 −0.8% 
(−145.3, 
58.6)
51 28/2639 24/2647 −17.6% 
(−112.0, 
34.3)
56 14/2665 11/2672 −27.9% 
(−211.3, 
46.1)
infection
66 17/2662 10/2657 −70.3% 
(−316.2, 
26.4)
31 31/cohort 
total not 
given
57/ cohort 
total not 
given
46.2% 
(15.3, 66.4)
33 15/ cohort 
total not 
given
21/ cohort 
total not 
given
28.7% (-
45.1, 65.8)
35 14/ cohort 
total not 
given
17/ cohort 
total not 
given
17.8% (-
77.1, 62.5)
45 24/ cohort 
total not 
given
26/ cohort 
total not 
given
7.8% (-
67.0, 49.3)
58 35/ cohort 
total not 
given
37/ cohort 
total not 
given
5.5% (-
54.3, 42.2)
Gardasil FUTURE I & 
FUTURE II – 
meta-analysis by 
Brown et al 09(5),
Efficacy 
population 
negative for 14 
HPV types,
6 month persistent 
infection
52 50/ cohort 
total not 
given
61/ cohort 
total not 
given
18.4% (-
20.6, 45.0)
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59 45/ cohort 
total not 
given
55/ cohort 
total not 
given
18.7 (-22.8, 
46.4)
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Supplement 8. Definition of trial sub-groups and sub-groups used in each trial
Characteristics of subgroupSub-group Trials 
using sub-
group 
(papers 
using sub-
group 
referenced) 
In bold 
where sub-
group used 
for 
powered 
outcomes
Negative 
on PCR 
on day 1 
for 
relevant 
HPV 
type 
Remained 
PCR 
negative to 
relevant 
HPV type to 
month 7 (1 
mth after 
third dose) 
Remained 
PCR 
negative to 
relevent 
HPV type 
on month 6
Negative 
on 
serology 
on day 1 
for 
relevant 
HPV 
type 
Receiv
ed 3 
doses 
within 
a year
No 
proto
col 
violat
ions
Included 
even if 
abnorm
al 
cytology 
on day 1
Other 
criteria
Start of case 
counting
Total 
Vaccine 
Cohort 
(TVC)
CVT(1) - n/a n/a - - - + Sexually 
active or 
became 
sexually 
active during 
the trial; 
Provided 
cervical 
samples
Not specified
NRT- 
Unrestricte
d 
susceptible 
population  
FUTURE 
I(2), 
FUTURE 
II(3), 
FUTURE 
+ - - + - - + Day after first 
vaccine 
(V501-005 
Day 1)
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(known as 
HNRT in 
V501-041)
III(4, 5), 
V501-
041(6)
Modified 
Intention 
To Treat
V501-
007(7, 8)
+ - - + - - + 30 days after 
day 1
Primary 
analysis
CVT(9) + - - - - - + Month 6
TVC-E (1) Zhu(10, 
11), 
Konno(12), 
VIVIANE(
13, 14)
+ - - + 
(Skinner 
+ for 
HPV16/1
8)
- Excluded 
if high-
grade or 
missing 
cytology
Day after first 
vaccine
TVC-E (2) Konno(15), 
PATRICI
A(16, 17)
- n/a n/a - - - Excluded 
if high-
grade or 
missing 
cytology
Day affter 
first vaccine 
(? Day after 
first vaccine- 
Konno Apr 
10)
Other PATRICIA
(18)
+ - - - Not 
specifie
d
Not 
specif
ied
Not 
specified
?Day after 
first vaccine
Naïve 
cohort
CVT(1) + n/a + + - - Excluded 
if 
CIN2+at 
baseline
No biopsy or 
treatment 
before 6 
month visit; 
sexually 
active or 
became 
sexually 
?Month 6
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active during 
the trial
TVC-naïve PATRICIA
(17, 19, 20)
DNA 
negative 
for all 14 
oncogeni
c types at 
month 0
- - Seronega
tive for 
HPV 16 
and 18
- Normal 
cytology 
at month 
0
Day after first 
vaccine
ITT (1) HPV-
001(21). 
HPV-
007(22, 
23), HPV-
023(24-26)
DNA 
negative 
for HR 
HPV 
DNA at 
month 0
- - - - - + Month 6
ITT (2) 
(Known as 
Full 
Analysis 
Set (FAS) 
Population 
in V501-
041)
FUTURE 
I(2), 
FUTURE 
II(27), 
FUTURE 
III(4, 5), 
CVT(28), 
VIVIANE(
13, 14),  
VPATRICI
A(17, 19, 
20, 29), 
V501-
041(6)
- n/a n/a - - - + Day after first 
vaccine 
(V501-005 
Day 1) 
Herrero- not 
documented)
ATP-E (1) PATRICI
A(17, 20)
+ - - + + + Excluded 
if high-
Day after 
third vaccine
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grade or 
missing 
cytology
ATP- Per-
protocol 
efficacy 
analysis (2)
FUTURE 
I(2), 
FUTURE 
II(27), 
FUTURE 
III(4, 5), 
V501-
007(7, 8), 
V501-
027(30), 
V501-
041(6)
+ + n/a + + + + Month 7
ATP 
cohort for 
efficacy 
(ATP-E) 
(3)
Zhu(10, 
11), 
Konno(12, 
15), 
VIVIANE(
13, 14)
+ n/a + + 
(Skinner 
+ for 
vaccine 
types, - 
for non-
vaccine 
types)
+ + Excluded 
if high-
grade or 
missing 
cytology
Month 6
According 
to Protocol 
(ATP) 
cohort (1)
CVT(28, 
31)
+ n/a + - + + + Month 6
ATP (2) HPV-
001(21), 
HPV-
DNA 
negative 
for HR 
n/a Negative to 
HPV 16/18 
DNA
Seronega
tive for 
HPV 
+ + Normal 
cytology 
at month 
Month 6
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This table gives the inclusion criteria for each of the sub-groups included in the trials and the list of trials that use each sub-group.
007(22, 
23), HPV-
023(24-26)
HPV 
DNA at 
month 0
16/18 0
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Supplement 9. Type assignment in disease endpoints
Vaccine and Trial Method used
Cervarix
HPV-001/ 007/ 023
HPV 16/18 infection detected in cytology 
specimen prior to colposcopy. Positive if 
contained HPV16 or 18 regardless of 
whether other HPV types detected.(1)
Cervarix
Konno
DNA testing from cytology specimen.(2)
Cervarix
PATRICIA
In PATRICIA trial primary analysis was 
on the basis of HPV16/18 being found in a 
lesion, they also did an additional analysis 
in Szarewski’s paper where they attributed 
causality in specimens where more than 
one HPV type was found based on finding 
the same HPV in one of two preceding 
cytological samples.(3)
Cervarix
Costa Rica Vaccine Trial (CVT)
Attributed causality when more than one 
HPV type was found in a lesion as an 
exploratory analysis(4)
Cervarix
VIVIANE
Tried to attribute causality when more 
than one HPV type was found in a 
lesion(5)
Cervarix
Zhu
Tried to attribute causality when more 
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than one HPV type was found in a 
lesion(6)
Gardasil
V501-007
Required evidence of persistent rather 
than incident infection with HPV DNA of 
the same type found in previous 
samples(7)
Gardasil
FUTURE I
HPV DNA to be found in an adjacent 
histologic section of the same biopsy 
site(8)
Gardasil
FUTURE II
HPV DNA to be found in an adjacent 
histologic section of the same biopsy 
site(9)
Gardasil
FUTURE III
HPV DNA to be found in an adjacent 
histologic section of the same biopsy 
site(10)
Gardasil
V501-027
HPV DNA detected in tissue from 
cervicovaginal samples or from 
biopsy.(11)
Gardasil
V501-041
HPV type 6/11/16/18 DNA detected in 
same tissue block(12)
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Supplement 10. Non-vaccine HPV type outcomes by trial 
Trial Paper Non-vaccine HPV 
outcomes considered
HPV-001 Harper 04(1) None considered
V501-007 Villa 06(2) None considered
FUTURE I Garland 07(3) CIN1+ due to any HPV 
type* 
FUTURE II Future II Study Group 
07(4)
CIN2+ due to any HPV 
type* 
Harper 06(5) CIN1+ and CIN2+ due to 
oncogenic HPV type** and 
due to any HPV type*** 
(includes if HPV DNA 
negative)
HPV-007
Romanowski 09(6) CIN1+ and CIN2+ due to 
any HPV type*** (includes 
if HPV DNA negative)
De Carvalho 10(7) Incident infection, 6-month 
and 12-month persistent 
infection (PI), CIN1+ and 
CIN2+ due to any 
oncogenic HPV type** 
Roteli-Martins 12(8) CIN1+ and CIN2+  due to 
any oncogenic HPV type** 
HPV-023
Naud 14(9) Incident infection any 
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oncogenic HPV type**, 
HPV 45, 31,33, 51 
separately; 6 and 12-month 
PI oncogenic HPV types**, 
CIN1+ and CIN2+ 
oncogenic types**
Konno Konno Jul 10(10) Incident infection, 12-
month PI, CIN1+ and 
CIN2+ due to any 
oncogenic type**
FUTURE III Castellsague 11(11) CIN2+ due to non-vaccine 
types 31, 33, 35, 39, 45, 51, 
52, 56, 58, or 59.
V501-027 Yoshikawa 13(12) None considered
PATRICIA Paavonen 07(13) 6 and 12-month PI due to 
HPV 31, 33, 45, 52, 58 
(separately and combined), 
any oncogenic type**, non-
vaccine oncogenic type# 
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Paavonen 09(14) 6-month PI, 12-month PI , 
CIN2+ due to HPV 31, 33, 
45, 52, 58 (separately and 
combined), any oncogenic 
type**, non-vaccine 
oncogenic type# 
Lehtinen 12(15) CIN1+, CIN2+ CIN3+, 
AIS due to any HPV 
type***
Herrero 11(16) 12-month PI with HPV 
31/33/45, other oncogenic 
types and any oncogenic 
type**** 
CVT
Hildesheim 14(17) CIN2+ due to any 
oncogenic HPV type and 
non-vaccine oncogenic 
HPV types##
VIVIANE Skinner 14(18) 6-month PI due HPV types 
31/33/35/52/58 (separately 
and combined), types 
39/45/58/68 (separately 
and combined), types 51, 
56, 66, to non-vaccine 
oncogenic types and any 
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oncogenic HPV types**
Wheeler 16(19) 6-month PI, 12-month PI, 
CIN1+, CIN+ due to non-
vaccine oncogenic types# 
individually or in 
combination; CIN1+and 
CIN2+ irrespective of HPV 
infection
Zhu 14(20) None consideredZhu
Zhu 17(21) Incident infection, 6 and 
12-month PI with 
oncogenic HPV types** 
and non-vaccine oncogenic 
types#
V501-041 Wei 18(22) None considered
* Not clear if tested for HPV presence or if so, what types tested for
** HPV types 16,18, 31,33,35,39,45,51,52,56, 58, 59, 66, and 68
*** Irrespective of HPV-DNA type and includes if HPV DNA negative
**** HPV types 16,18, 31,33,35,39,45,51,52,56, 58, 59, 66, 68 and 73- specifies that 
cannot differentiate between types 68 and 73
# Non-vaccine oncogenic types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68
## HPV types 31,33,35,39,45,51,52,56, 58, 59, 66, 68 and 73- specifies that cannot 
differentiate between types 68 and 73
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